. A diabetic mouse model was produced using a mutant human hepatocyte nuclear factor-1α gene (HNF1αP291fsinsC) regulated by the porcine insulin promoter. The functionality of two different constructs containing HNF1αP291fsinsC, termed PD1 and PD2 (cytomegalovirus enhancer minus and plus), were examined in transgenic mice. The blood glucose levels and body weights of the PD1 transgenic mice did not differ from their non-transgenic littermates over the period from 3 to 8 weeks of age. Conversely, the PD2 transgenic mice exhibited hyperglycemia and decreased body weight. Western blot analysis demonstrated that mutant HNF-1α protein (HNF1αP291), derived from the PD2 transgene, was expressed in the PD2 mice. Morphometric studies of the pancreas of a PD2 mouse revealed that the number of pancreatic islets present was less than that in the nontransgenic mice, indicating disturbed islet neogenesis. These results suggest that impaired insulin secretion in disrupted islets causes hyperglycemia. In addition, the phenotype of PD2 transgenic mice similar to that of the HNF-1α gene-deficient mouse, which displays growth retardation and impaired viability. These results indicate that HNF1αP291 expression driven by the porcine insulin promoter, together with the cytomegalovirus enhancer, induces a diabetic phenotype in transgenic mice.
To date, no transgenic animals using the porcine insulin promoter have been reported, but the human and rat insulin promoters are commonly used when generating transgenic animals. In this study, the activity of the porcine insulin promoter in mouse insulinoma NIT-1 cells was investigated and production of transgenic mice using two different HNF1αP291fsinsC expression vectors was attempted. In this paper, the functionality of the vectors encoding the porcine insulin promoter and the phenotype of the transgenic mice are examined and discussed.
Materials and Methods

Animal care
All of the animal experiments in this study were approved by Institutional Animal Care and Use Committee of Meiji University (IACUC-04-004).
Construction of transgene and reporter vectors
A transgene, designated as PD1, consisted of the pig insulin promoter, mutant human HNF-1α (HNF1αP291fsinsC) cDNA, the simian virus 40 (SV40) polyadenylation signal, and the chicken β-g l o b i n i n s u l a t o r s , a s s h o w n i n F i g . 1 B . Approximately 680 bp of the 5' flanking region from the initiation codon (ATG) of the porcine insulin gene was amplified, to serve as the pig insulin promoter, by polymerase chain reaction (PCR) using the following primers with EcoRI restriction sites (underlined): 5'-GAATTC-ACCGCCGCAGCAGCCCGGGGT-3' and 5'-GAATTCGGCGGGGGGTGAGGACCT-GGG-3'. Wild-type human HNF-1α (hHNF-1α, Accession No. NM000545) cDNA was amplified by PCR from human liver cDNA (Clontech, Mountain View, CA, USA) using the following primers with EcoRI and B a m H I r e s t r i c t i o n s i t e s ( u n d e r l i n e d ) : 5 ' -GAATTCTCTAAACTGAGCCAGCTGCAGACG-3' and 5'-GGATCCACAAGGCCACGCTGATCCA-GGGCC-3'. To generate the HNF1αP291fsinsC mutation, a cytosine nucleotide was added to the hHNF-1α cDNA by site-directed mutagenesis with the following primers: 5'-GTACAGCGGG-C C C C C C C C C A G G G C C A G G C C -3 ' a n d 5 ' -GGCCTGGCCCTGGGGGGGGGCCCGC-TGTAC-3'. The addition of the cytosine nucleotide results in a frameshift mutation at amino acid position 291, and consequently, a pre-mature stop codon is generated and leads to synthesis of an incomplete protein of 315 amino acids (Fig. 1A) . The SV40 polyadenylation signal sequence was amplified by PCR from the pEGFP-N1 vector (Clontech) using the following primers with BamHI and XbaI r e s t r i c t i o n s i t e s ( u n d e r l i n e d ) : 5 ' -GGATCCGCAGCTTATAATGGTTAC-3' and 5'-TCTAGAACAAACCACAACTAGAAT-3'. The sequence of the chicken β-globin insulator was amplified by PCR from the Cyt-1 expression vector, which was donated by Dr. N. Ishii (Tokai University). All amplified products were s u b c l o n e d i n t o p C R 4 B l u n t -T O P O v e c t o r (Invitrogen, Carlsbad, CA, USA), and nucleotide sequences were confirmed using a Dye Terminator Cycle Sequencing Kit and an ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The sequenced HNF1αP291fsinsC and SV40 polyadenylation signal were digested with EcoRI and BamHI, and BamHI and XbaI, respectively, and the digested fragments were inserted into pBluescript SK(-) (Stratagene, La Jolla, CA, USA). Subsequently, the porcine promoter was inserted into the EcoRI site of this vector. The EcoRI restriction site, GAATTC, on the 3' side of the porcine insulin promoter was mutated to ATGGTT in order to generate a start codon by site-directed mutagenesis using the following two sets of primers: 5'-CCTCACCCCCCGCCATATTTTCT-AACTGAGC-3' and 5'-GCTCAGTTTAGAAAA-TATGGCGGGGGG-TGAGG-3' and 5'-CACCCC-CCGCCATGGTTTCTAAACTGAGCC-3' and 5'-GGCTCAGTTTAGAAACCATGGCGGGGGGTG-3'. The chicken β-globin insulator sequences were introduced at both the 5' and 3' ends of the constructing vector because it is known that enhancers of host genes at the site of integration can reduce the specificity of expression. These positional effects have been reported to be attenuated by adding the 5' HS insulator region from the chicken β-globin gene locus [22, 23] .
For construction of the PD2 vector, a 408 bp enhancer region within the human cytomegalovirus (CMV) immediate-early promoter sequence was amplified by PCR from pEGFP-N1 using the appropriate primers. The amplified CMV enhancer was coupled to the porcine insulin promoter of the PD1 vector in order to generate the PD2 vector (Fig.  1B) . The DNA sequences of these constructs were verified as described above.
For in vitro reporter assays, the enhanced green fluorescent protein (EGFP) reporter vector, termed Ptg7CMV(-), was constructed (Fig. 1C) . The porcine insulin promoter sequence was coupled with EGFP gene in reporter vector pEGFP-N1, which had the human CMV immediate early promoter/enhancer region deleted. The CMV enhancer sequence was inserted into the 5' region of the porcine insulin promoter in the Ptg7CMV(-) vector in order to generate the Ptg7CMVen(+) vector (Fig. 1C) .
In vitro reporter assay
For the in vitro transfection experiments, an insulin-producing mouse insulinoma NIT-1 cell line and non-insulin producing human cervical carcinoma HeLa cell line were used and cultured in HAM's F-12K (Sigma-Aldrich, St. Louis, MO, USA) containing 10% (v/v ) FBS and RPMI 1640 (Invitrogen), respectively. These cells were passaged 1 day prior to transfection and plated in 24-well plates at a cell density of 4 × 10 4 cells/well. After 24 h incubation, these cells were transfected with either Ptg7CMV(-) or Ptg7CMVen(+) using LipofectAMINE PLUS reagent (Invitrogen) for 24 h. After 24 h, the transfection medium was exchanged for the preceding culture medium containing 20 nM glucagon-like peptide (GLP)-1 (Sigma-Aldrich) to induce insulin production [24] . Three days later (72 h), the transfected cells were observed under fluorescence microscopy and the number of cells expressing EGFP was determined.
Production and identification of transgenic mice
The transgene fragment was excised from the PD1 and PD2 vectors by enzymatic digestion with the restriction endonucleases KpnI and NotI, separated by gel electrophoresis, and purified with a GENECLEAN II Kit (Qbiogene, Irvine, CA, USA). Pronuclear stage embryos were collected from the oviducts of superovulated BDF1 females (Clea Japan, Tokyo, Japan) that had been mated with BDF1 males. The purified DNA (10 ng/µl) fragments were microinjected into male pronuclei of BDF1 embryos using an Eppendorf microinjector (FemtoJet, Hamburg, Germany) and Narishige microinjectors (MO-202U; Narishige, Tokyo, Japan). The injected embryos were transferred to the oviducts of pseudopregnant ICR strain mice. The founders of the generated transgenic mice were identified by PCR and Southern blot analyses of tail DNA taken at 3 weeks of age.
Measurement of blood glucose and body weight
Whole blood was collected from the tail veins of the obtained founder transgenic mice and nontransgenic mice. Blood glucose levels were determined using a Glucocard G meter and G sensor (Arkray, Kyoto, Japan). Transgenic and non-transgenic mice were fasted for 16 h before measurement of the blood glucose level. The blood glucose levels and body weights of the transgenic and non-transgenic mice were measured over a period that ranged from 3 to 8 weeks of age.
Reverse transcription-PCR
Total RNAs were extracted using Isogen RNA extraction reagent (Nippon Gene, Tokyo, Japan), according to th e man ufacturer's protocol.
Contaminating genomic DNA in the RNA extracts was removed by treatment with DNase I. First s t r a n d c D N A w a s s y n t h e s i z e d b y r e v e r s e transcription reaction of the total RNA using SuperScript III RNaseH-Reverse Transcriptase (Invitrogen) together with dNTPs and oligo dT primers. The following primers were used for the specific PCR amplification of mutant human HNF-1α (HNF1αP291fsinsC): 5'-AGGACCTGAGCCT-GCCGAGCAAC-3' and 5'-AGGGCTCTCCATA-GGCCCAGGCT-3'. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified as the PCR control using the following primers:
Western blot analysis
After sacrifice by cervical dislocation, dissected livers of transgenic and non-transgenic mice were homogenized in RIPA buffer [1% NP-40 (v/v), 0.1% sodium deoxycholate (w/v), 150 mM NaCl, 50 mM Tris-HCl (pH 7. Approximately 70 µg of protein from liver extracts was subjected to 10% SDS-PAGE and transferred by electroblotting to a Hybond-P PVDF membrane (GE Healthcare Bio-Sciences, Piscataway, NJ, USA). The membranes were blocked for 16 h at 4 C with Block Ace blocking reagent (Dainippon Sumitomo Pharma, Osaka, Japan). After blocking, the m e m b r a n e s w e r e i n c u b a t e d w i t h m o u s e monoclonal anti-HNF-1α antibody (1:250 dilution; BD Biosciences, Franklin Lakes, NJ, USA) for 1 h at room temperature and subsequently incubated with alkaline phosphatase conjugated anti-mouse IgG antibody (1:30,000 dilution; Sigma-Aldrich) for 1 h at room temperature. The blot was developed using BCIP/NBT liquid substrate reagent (SigmaAldrich).
Histological analysis
PD2 transgenic and control mice were sacrificed by cervical dislocation. Dissected pancreases were fixed in 10% neutral buffered formalin solution (Wako Pure Chemical Industries, Osaka, Japan), embedded in paraffin, sectioned, and stained with hematoxylin and eosin using standard methods.
Statistics
All data, except for blood glucose levels and body weights of the PD2 mouse, are given as means ± SD. The statistical significance of the differences between groups was determined using the Student's t-test.
Results
In vitro reporter assay for pig insulin promoter functionality
To determine whether the cloned porcine insulin promoter was functional, in vitro reporter assays were performed using NIT-1 (insulin secretion) and HeLa (non-insulin secretion) cells transfected with the Ptg7CMV(-) and Ptg7CMVen(+) vectors. Glucagon-like peptide-1 (GLP-1) has recently been reported to induce insulin production [24] . Therefore, GLP-1 was added to the media after tranfection. For both the GLP-1 treated and untreated NIT-1 cells from the Ptg7CMV(-) vector, a signal could be detected after 72 h, whereas no EGFP expression was detected in HeLa cells ( Fig.  2A ). There was a statistically significant increase (P<0.01) in the level of EGFP expression in NIT-1 cells treated with GLP-1 relative to untreated cells, indicating that the cloned porcine insulin promoter was indeed functional. Thus, it appears that the cloned porcine insulin promoter confers cell-type specific expression. Overall, the functionality of the pig insulin promoter was confirmed using an EGFP reporter assay.
Expression of the other EGFP reporter construct, Ptg7CMVen(+), and the encoding of the CMV enhancer at the 5' end of the porcine insulin promoter were also examined. The CMV enhancer is widely regarded as the most powerful known transcriptional control element. In NIT-1 cells treated with GLP-1, the level of EGFP reporter gene expression from Ptg7CMVen(+) was approximately 20-fold higher than in Ptg7CMV(-) transfected cells (Fig. 2B) . Unlike the case for Ptg7CMV(-) transfected cells, EGFP expression from the Ptg7CMVen(+) vector was observed not only in NIT-1 cells but also in HeLa cells (data not shown). This indicates that expression of reporter genes under the control of the porcine insulin promoter, together with the CMV enhancer, can be observed in various cell-types. Thus, the expression of EGFP driven by the insulin promoter was significantly enhanced in the NIT-1 cells through coupling of the porcine insulin promoter with a CMV enhancer on the promoter's 5'end. This coupling also caused the loss of cell type-specific expression. All in vitro EGFP reporter experiments were performed four times with similar results. 
PD1 transgenic mice
Transgenic mice were produced following activity confirmation of the pig insulin promoter by in vitro reporter assays. Microinjection of BDF1 embryos with the PD1 construct yielded forty-two progeny. PCR and Southern blot analyses revealed three transgenic founders. The blood glucose levels and body weights of the PD1 transgenic mice were measured from 3 to 8 weeks of age. During this period, there was no difference between the transgenic and non-transgenic mice in terms of their blood glucose levels or body weights (data not shown). RT-PCR analysis was performed to investigate PD1 transgene expression in the pancreases of the transgenic mice, but PD1 transgenic mRNA could not be detected (data not shown).
PD2 transgenic mice
Fifty-six mice were born after microinjection of BDF1 embryos. Six of the produced mice were identified as being PD2 transgenic mice by PCR and Southern blot analyses. One female mouse (#9-2) became severely diabetic and two female mice (#29-3 and #33-2) died at 2 to 3 weeks of age. The two dead mice were clearly smaller than their non-transgenic littermates. The rest of the PD2 mice (#32-4, #35-2 and #37-2) exhibited no detectable diabetic phenotypes from 3 to 8 weeks of age. The blood glucose level of mouse #9-2 was significantly increased compared to that of the non-transgenic mice. At 8 weeks of age, the blood glucose level of mouse #9-2 was approximately eight times higher than that of the non-transgenic mice (Fig. 3A) . Furthermore, the body weight of mouse #9-2 was approximately 40% lower than that of the nontransgenic mice at 8 weeks of age (Fig. 3B) . In addition to hyperglycemia, mouse #9-2 exhibited marked growth retardation, and its uterus and ovaries were at least 4 times smaller than those of the non-transgenic mice at ten weeks of age ( Fig. 3C and  D) . To examine expression of the PD2 construct in the PD2 mouse (#9-2) in various organs, RT-PCR analysis was performed for the brain, lung, heart, liver, pancreas, spleen, and kidney. As was the case for the in vitro reporter assay, PD2 transgene expression was non-specific and could be detected in all 7 organs included in this analysis (Fig. 4) . Southern blot analysis revealed that mouse #9-2, which displayed a diabetic phenotype, contained approximately 10 copies of the transgene in its genome. Mice #29-3 and #33-2, which died at 2 to 3 weeks of age, contained approximately 20 and 100 copies of the transgene in their genomes, respectively. The three mice (#32-4, #35-2 and #37-2) that did not exhibit a diabetic phenotype contained less than 10 copies of the transgene in their genomes (data not shown).
We attempted to establish a PD2 mouse (#9-2) line, however, attempts to obtain offspring from this mouse had to be abandoned because the mouse developed severe hyperglycemia and was clearly weak. Furthermore, as mentioned previously, the ovaries and uterus of mouse #9-2 were at least four times smaller than the non-transgenic mice (Fig.  3D) , indicating that the fertility of mouse #9-2 was severely impaired.
Western blot analysis
Protein extracts from the dissected livers of PD2 mice (#9-2, #29-3 and #33-2) were subjected to western blot analysis. Mutant human HNF-1α protein (HNF1αP291), encoded by the PD2 transgene, was approximately half the molecular weight of the endogenous mouse HNF-1α protein and was detected in samples from PD2 mice. However, only endogenous HNF-1α was observed in the control mouse (Fig. 5) . Despite the fact that mouse #33-2 harbored a high number of copies of the PD2 transgene (approx. 100 copies) in its genome, there was little difference in the level of HNF1αP291 expression between the three PD2 mice.
Histological analysis
The number of pancreatic islets in the PD2 mouse (#9-2) was less than in the control mice and the size of these islets was smaller than in the control mice, indicating disturbed islet neogenesis (Fig. 6A and  B) . These results suggest that impaired insulin secretion in the disrupted islets caused the hyperglycemia in mouse #9-2. In addition, the acinar cells of the pancreas morphologically transgenic mouse. Total RNA was prepared from seven different organs (brain, lung, heart, liver, pancreas, spleen, kidney) from a PD2 mouse and used for RT-PCR. Twenty-five cycles of the PCR procedure were performed to detect the mRNA of mutant human HNF1α (top) and GAPDH (bottom). displayed a variety of changes including expansion and necrosis (Fig. 6B ).
Discussion
Two vectors were constructed in order to overexpress a mutated human hepatocyte nuclear factor-1α gene (HNF1αP291fsinsC) under the control of the porcine insulin promoter (Fig. 1B) and to examine the functionality of the vectors in transgenic mice. To our knowledge, the production of a diabetic animal model using the porcine insulin gene promoter has never been reported before, although the rat insulin I and II gene promoters and the human insulin promoter have frequently been utilized for pancreatic β-cell-specific expression of target genes in transgenic mice [21, 25, 26] . To confirm the functionality of the cloned porcine insulin promoter, in vitro reporter assays were performed using two EGFP reporter vectors, Ptg7CMV(-) and Ptg7CMVen(+) (Fig. 1C) . The in vitro transfection experiments showed that EGFP reporter gene expression driven by the porcine insulin promoter can be detected in insulin producing mouse insulinoma NIT-1 cells (Fig. 2) . Furthermore, they showed that the activity of this promoter can be significantly increased through the addition of GLP-1 to the media, indicating that the porcine insulin promoter was indeed functional. In addition, EGFP expression from the Ptg7CMV(-) construct could not be detected in human breast cancer cell line MCF7. Unlike the case for Ptg7CMV(-) transfected cells, EGFP expression from the Ptg7CMVen(+) vector was also observed in MCF7 (data not shown). Moreover, confirmation of promoter functionality was achieved through construction of other EGFP vectors driven by the porcine insulin promoter (data not shown).
In the PD1 transgenic mice, no detectable hyperglycemia was observed, which was contrary our expectations. In addition, the inbred progeny of PD1 the mice also showed normal blood glucose levels (data not shown). Hagenfeldt-Johansson et a l . r e p o r t e d t h a t f e m a l e t r a n s g e n i c m i c e overexpressing mutant HNF-1α driven by the rat insulin promoter, remained normoglycemic, but exhibited glucose intolerance [17] . Although a glucose tolerance test was not performed in this study, the PD1 mice did not exhibit a clear diabetic phenotype. It is uncertain whether this was the result of differences in function between the porcine and rat insulin promoters. Furthermore, as described in man y reports addressing the production of transgenic mice, the functionality of the transgene depends on the integration site in the host genome. This may account for the phenotype of the PD1 mice described in this study.
For the PD2 vector, the human CMV enhancer sequence was inserted in order to increase the expression of HNF1αP291fsinsC (Fig. 1B) . The use of a cellular promoter together with a viral transcription regulatory element, such as CMV and SV40 enhancers, is a promising method for enhancement of the expression of transgenes. CMV enhancer contributes to gene expression in a wide range of cell types and transgenic mice by acting as a pan-active control element [27] [28] [29] . On RT-PCR analysis, the PD2 transgene was expressed in all organs studied. The addition of CMV enhancer to the PD2 transgene under the control of the porcine insulin promoter resulted in the loss of pancreasspecific transgene expression. However, the addition of a CMV enhancer does not always cause the loss of tissue-specific expression properties. A hybrid promoter containing the platelet-derived growth factor B-chain (PDGF-β) promoter with CMV enhancer has been reported to exhibit neuron-specific expression in cultured cells, which indicates that the hybrid promoter retained the neuronal characteristics of the PDGF-β promoter [30] . In addition, a transgene including the rat insulin I promoter and SV40 enhancer, which is kn own to be a potent enhancer, exhibited pancreatic islet-specific expression in transgenic mice [31] . Thus, it has been reported that tissuespecific expression can be retained, even in the presence of CMV and SV40 enhancers. In this study, the construct of the porcine insulin promoter together with CMV enhancer lacked tissue-specific expression. However, the PD2 transgenic mice, which exhibited higher blood glucose levels and lower body weights than the non-transgenic mice, were obtained through the addition of CMV enhancer. Furthermore, two PD2 mice (#29-3 and #33-2) were significantly smaller and weaker than their non-transgenic littermates and, consequently, died before reaching three weeks of age. Histological analyses of the pancreas of a PD2 transgenic mouse (#9-2) demonstrated that the number of pancreatic islets was less than in a control non-transgenic mouse (Fig. 6 ). This indicates that islet neogenesis was disrupted and, consequently, that insulin secretion was evidently impaired. Defective insulin secretion caused by islet dysfunction has typically been observed in MODY 3 patients harboring a mutated form of the HNF-1α gene, including the HNF1αP291fsinsC mutation. The results presented here are consistent with the results obtained by Hagenfeldt-Johansson et al. and Yamagata et al., who generated mice overexpressing mutant HNF-1α under the control of the rat insulin promoter [17, 21] . In addition to hyperglycemia, one PD2 transgenic mouse (#9-2) displayed retarded growth, including a smaller uterus and ovaries (Fig. 3C and D) . This phenotype was not observed in the MODY 3-type mice generated by Hagenfeldt-Johansson et al. and Yamagata et al. Interestingly, the phenotype of mouse #9-2 was similar to that of HNF-1α-deficient mice in certain respects. For example, HNF-1α gene-deficient (-/-) mice have been reported to exhibit growth retardation, infertility, and hyperglycemia with body weights of only 50-60% of that of their HNF-1α gene (+/-) and HNF-1α gene (+/+) littermates at 5 weeks of age [11, 13, 14] . In contrast, HNF-1α gene-deficient (-/-) mice did not display the embryonic lethality phenotype, but the lifespan of almost all these mice was reportedly very short (less than 3 months), and 50% of them died within a month [11] . Similar to HNF-1α-deficient mice, the body weight of mouse #9-2 was only 40% of that of the non-transgenic mice. Furthermore, a third of the PD2 transgenic mice obtained in this study were smaller than their nontransgenic littermates and were dead within a month. In addition, the retarded growth rate of the PD2 mice closely resembled that of HNF-1α gene (-/-) mice. In MODY 3 subjects, a distinct diabetic phenotype is observed, but they do not exhibit any dramatic growth retardation, such as small reproductive organs [32] . It has been reported that HNF-1α gene (-/-) mice possess reproductive organs that exhibit dramatic hypoplasia and Larontype dwarfism (Laron syndrome, LS) [11, 14] . LS is caused by deletions or mutations in the growth hormone receptor (GHR) gene resulting in dysfunction of the GHR [33] . LS patients exhibit growth retardation, such as small genitalia and gonads, and recombinant human insulin growth factor I (IGF-I) is administered as a therapy for LS patients because their IGF-I levels are severely depressed [34] [35] [36] [37] [38] . In a manner similar to LS disease, HNF-1α deficiency causes a reduction in IGF-I gene expression [14] . Indeed, HNF-1α regulatory elements have been found in the promoter region of the IGF-I gene, and HNF-1α appears to be the major trans-activator of the IGF-I gene [39] [40] [41] . This is potentially the functional reason for the growth retardation observed in the PD2 mice.
In this study, transgenic mice were generated using two different mutant HNF-1α expression vectors under the control of porcine insulin promoter. Although the PD1 mice did not exhibit a distinct diabetic phenotype, the PD2 mice obtained exhibited hyperglycemia and growth retardation. Further studies will entail generation of a diabetic model pig using the PD2 construct assessed in this study. Despite the fact that microinjection of exogenous DNA into male pronuclei has proven to be highly successful in the generation of transgenic animals, in mice particularly as shown in this study, this technique has proven to be far less efficient in farm animals [42] , including the pig. Recently, gene transfer using intra-cytoplasmic sperm injection (ICSI-mediated gene transfer) and in vitro-matured oocytes has been reported as an efficient alternative procedure for producing transgenic pigs [43] . Generation of a diabetic pig using the PD2 construct and the ICSI-mediated gene transfer method would mark a significant contribution to the ongoing efforts to advance the study and treatment of diabetes.
